Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 79

1.

Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial.

Tan AR, Wright GS, Thummala AR, Danso MA, Popovic L, Pluard TJ, Han HS, Vojnović Ž, Vasev N, Ma L, Richards DA, Wilks ST, Milenković D, Yang Z, Antal JM, Morris SR, O'Shaughnessy J.

Lancet Oncol. 2019 Sep 27. pii: S1470-2045(19)30616-3. doi: 10.1016/S1470-2045(19)30616-3. [Epub ahead of print]

PMID:
31575503
2.

A phase I trial of MK-2206 and hydroxychloroquine in patients with advanced solid tumors.

Mehnert JM, Kaveney AD, Malhotra J, Spencer K, Portal D, Goodin S, Tan AR, Aisner J, Moss RA, Lin H, Bertino JR, Gibbon D, Doyle LA, White EP, Stein MN.

Cancer Chemother Pharmacol. 2019 Oct;84(4):899-907. doi: 10.1007/s00280-019-03919-x. Epub 2019 Aug 28.

PMID:
31463691
3.

Open-Label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer.

Vinayak S, Tolaney SM, Schwartzberg L, Mita M, McCann G, Tan AR, Wahner-Hendrickson AE, Forero A, Anders C, Wulf GM, Dillon P, Lynce F, Zarwan C, Erban JK, Zhou Y, Buerstatte N, Graham JR, Arora S, Dezube BJ, Telli ML.

JAMA Oncol. 2019 Jun 13. doi: 10.1001/jamaoncol.2019.1029. [Epub ahead of print]

4.

The current state of molecular testing in the treatment of patients with solid tumors, 2019.

El-Deiry WS, Goldberg RM, Lenz HJ, Shields AF, Gibney GT, Tan AR, Brown J, Eisenberg B, Heath EI, Phuphanich S, Kim E, Brenner AJ, Marshall JL.

CA Cancer J Clin. 2019 Jul;69(4):305-343. doi: 10.3322/caac.21560. Epub 2019 May 22. Review.

5.

Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study.

Adams S, Schmid P, Rugo HS, Winer EP, Loirat D, Awada A, Cescon DW, Iwata H, Campone M, Nanda R, Hui R, Curigliano G, Toppmeyer D, O'Shaughnessy J, Loi S, Paluch-Shimon S, Tan AR, Card D, Zhao J, Karantza V, Cortés J.

Ann Oncol. 2019 Mar 1;30(3):397-404. doi: 10.1093/annonc/mdy517.

PMID:
30475950
6.

Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study.

Adams S, Loi S, Toppmeyer D, Cescon DW, De Laurentiis M, Nanda R, Winer EP, Mukai H, Tamura K, Armstrong A, Liu MC, Iwata H, Ryvo L, Wimberger P, Rugo HS, Tan AR, Jia L, Ding Y, Karantza V, Schmid P.

Ann Oncol. 2019 Mar 1;30(3):405-411. doi: 10.1093/annonc/mdy518.

PMID:
30475947
7.

Study of Tourniquet Use in Simulated First Aid: User Judgment.

Kragh JF Jr, Tan AR, Newton NJ, Aden JK 3rd, Dubick MA.

J Spec Oper Med. Fall 2018;18(3):15-21.

PMID:
30222831
8.

Collective variable discovery and enhanced sampling using autoencoders: Innovations in network architecture and error function design.

Chen W, Tan AR, Ferguson AL.

J Chem Phys. 2018 Aug 21;149(7):072312. doi: 10.1063/1.5023804.

PMID:
30134681
9.

Personalizing aromatase inhibitor therapy in patients with breast cancer.

Hamadeh IS, Patel JN, Rusin S, Tan AR.

Cancer Treat Rev. 2018 Nov;70:47-55. doi: 10.1016/j.ctrv.2018.07.014. Epub 2018 Jul 23. Review.

PMID:
30086432
10.

Development of poly(ADP-ribose) polymerase inhibitors in the treatment of BRCA-mutated breast cancer.

Sulai NH, Tan AR.

Clin Adv Hematol Oncol. 2018 Jul;16(7):491-501. Review.

PMID:
30067621
11.

New and Established Models of Limb Tourniquet Compared in Simulated First Aid.

Kragh JF Jr, Newton NJ, Tan AR, Aden JK 3d, Dubick MA.

J Spec Oper Med. Summer 2018;18(2):36-41.

PMID:
29889953
12.

Safety and pharmacokinetics of veliparib extended-release in patients with advanced solid tumors: a phase I study.

Werner TL, Sachdev J, Swisher EM, Gutierrez M, Kittaneh M, Stein MN, Xiong H, Dunbar M, Sullivan D, Komarnitsky P, McKee M, Tan AR.

Cancer Med. 2018 Jun;7(6):2360-2369. doi: 10.1002/cam4.1488. Epub 2018 May 7.

13.

Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer.

Rugo HS, Delord JP, Im SA, Ott PA, Piha-Paul SA, Bedard PL, Sachdev J, Tourneau CL, van Brummelen EMJ, Varga A, Salgado R, Loi S, Saraf S, Pietrangelo D, Karantza V, Tan AR.

Clin Cancer Res. 2018 Jun 15;24(12):2804-2811. doi: 10.1158/1078-0432.CCR-17-3452. Epub 2018 Mar 20.

14.

Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Brain Metastases Working Group.

Lin NU, Prowell T, Tan AR, Kozak M, Rosen O, Amiri-Kordestani L, White J, Sul J, Perkins L, Beal K, Gaynor R, Kim ES.

J Clin Oncol. 2017 Nov 20;35(33):3760-3773. doi: 10.1200/JCO.2017.74.0761. Epub 2017 Oct 2.

PMID:
28968165
15.

Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.

Kim SB, Dent R, Im SA, Espié M, Blau S, Tan AR, Isakoff SJ, Oliveira M, Saura C, Wongchenko MJ, Kapp AV, Chan WY, Singel SM, Maslyar DJ, Baselga J; LOTUS investigators.

Lancet Oncol. 2017 Oct;18(10):1360-1372. doi: 10.1016/S1470-2045(17)30450-3. Epub 2017 Aug 8. Erratum in: Lancet Oncol. 2018 Dec;19(12):e667.

16.

Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York Cancer Consortium trial.

Adelson K, Ramaswamy B, Sparano JA, Christos PJ, Wright JJ, Raptis G, Han G, Villalona-Calero M, Ma CX, Hershman D, Baar J, Klein P, Cigler T, Budd GT, Novik Y, Tan AR, Tannenbaum S, Goel A, Levine E, Shapiro CL, Andreopoulou E, Naughton M, Kalinsky K, Waxman S, Germain D.

NPJ Breast Cancer. 2016 Dec 14;2:16037. doi: 10.1038/npjbcancer.2016.37. eCollection 2016.

17.

Fibroblast-like synoviocyte mechanosensitivity to fluid shear is modulated by interleukin-1α.

Estell EG, Murphy LA, Silverstein AM, Tan AR, Shah RP, Ateshian GA, Hung CT.

J Biomech. 2017 Jul 26;60:91-99. doi: 10.1016/j.jbiomech.2017.06.011. Epub 2017 Jun 28.

18.

A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer.

Rugo HS, Trédan O, Ro J, Morales SM, Campone M, Musolino A, Afonso N, Ferreira M, Park KH, Cortes J, Tan AR, Blum JL, Eaton L, Gause CK, Wang Z, Im E, Mauro DJ, Jones MB, Denker A, Baselga J.

Breast Cancer Res Treat. 2017 Oct;165(3):601-609. doi: 10.1007/s10549-017-4375-5. Epub 2017 Jul 5.

19.

A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer.

Baselga J, Morales SM, Awada A, Blum JL, Tan AR, Ewertz M, Cortes J, Moy B, Ruddy KJ, Haddad T, Ciruelos EM, Vuylsteke P, Ebbinghaus S, Im E, Eaton L, Pathiraja K, Gause C, Mauro D, Jones MB, Rugo HS.

Breast Cancer Res Treat. 2017 Jun;163(3):535-544. doi: 10.1007/s10549-017-4199-3. Epub 2017 Mar 21.

20.

Concise Review: Mesenchymal Stem Cells for Functional Cartilage Tissue Engineering: Taking Cues from Chondrocyte-Based Constructs.

Tan AR, Hung CT.

Stem Cells Transl Med. 2017 Apr;6(4):1295-1303. doi: 10.1002/sctm.16-0271. Epub 2017 Feb 8. Review.

21.

Clinical Actionability of Comprehensive Genomic Profiling for Management of Rare or Refractory Cancers.

Hirshfield KM, Tolkunov D, Zhong H, Ali SM, Stein MN, Murphy S, Vig H, Vazquez A, Glod J, Moss RA, Belyi V, Chan CS, Chen S, Goodell L, Foran D, Yelensky R, Palma NA, Sun JX, Miller VA, Stephens PJ, Ross JS, Kaufman H, Poplin E, Mehnert J, Tan AR, Bertino JR, Aisner J, DiPaola RS, Rodriguez-Rodriguez L, Ganesan S.

Oncologist. 2016 Nov;21(11):1315-1325. doi: 10.1634/theoncologist.2016-0049. Epub 2016 Aug 26.

22.

Lack of pharmacokinetic drug-drug interaction between ramucirumab and paclitaxel in a phase II study of patients with advanced malignant solid tumors.

Chow LQ, Smith DC, Tan AR, Denlinger CS, Wang D, Shepard DR, Chaudhary A, Lin Y, Gao L.

Cancer Chemother Pharmacol. 2016 Aug;78(2):433-41. doi: 10.1007/s00280-016-3098-3. Epub 2016 Jul 5.

23.

High seeding density of human chondrocytes in agarose produces tissue-engineered cartilage approaching native mechanical and biochemical properties.

Cigan AD, Roach BL, Nims RJ, Tan AR, Albro MB, Stoker AM, Cook JL, Vunjak-Novakovic G, Hung CT, Ateshian GA.

J Biomech. 2016 Jun 14;49(9):1909-1917. doi: 10.1016/j.jbiomech.2016.04.039. Epub 2016 May 10.

24.

Cutaneous manifestations of breast cancer.

Tan AR.

Semin Oncol. 2016 Jun;43(3):331-4. doi: 10.1053/j.seminoncol.2016.02.030. Epub 2016 Feb 23. Review.

PMID:
27178684
25.

Bilateral versus unilateral instrumentation in spinal surgery: Systematic review and trial sequential analysis of prospective studies.

Phan K, Leung V, Scherman DB, Tan AR, Rao PJ, Mobbs RJ.

J Clin Neurosci. 2016 Aug;30:15-23. doi: 10.1016/j.jocn.2016.01.013. Epub 2016 Apr 7. Review.

PMID:
27068653
26.

Cyclin-dependent kinase-mediated phosphorylation of breast cancer metastasis suppressor 1 (BRMS1) affects cell migration.

Roesley SN, Suryadinata R, Morrish E, Tan AR, Issa SM, Oakhill JS, Bernard O, Welch DR, Šarčević B.

Cell Cycle. 2016;15(1):137-51. doi: 10.1080/15384101.2015.1121328.

27.

Cytokine preconditioning of engineered cartilage provides protection against interleukin-1 insult.

Tan AR, VandenBerg CD, Attur M, Abramson SB, Knight MM, Bulinski JC, Ateshian GA, Cook JL, Hung CT.

Arthritis Res Ther. 2015 Dec 14;17:361. doi: 10.1186/s13075-015-0876-y.

28.

Pharmacokinetics of eribulin mesylate in cancer patients with normal and impaired renal function.

Tan AR, Sarantopoulos J, Lee L, Reyderman L, He Y, Olivo M, Goel S.

Cancer Chemother Pharmacol. 2015 Nov;76(5):1051-61. doi: 10.1007/s00280-015-2878-5. Epub 2015 Oct 3.

29.

Phase II randomized clinical trial evaluating neoadjuvant chemotherapy regimens with weekly paclitaxel or eribulin followed by doxorubicin and cyclophosphamide in women with locally advanced HER2-negative breast cancer: NSABP Foundation Study FB-9.

Abraham J, Robidoux A, Tan AR, Limentani S, Sturtz K, Shalaby I, Alcorn H, Buyse ME, Wolmark N, Jacobs SA.

Breast Cancer Res Treat. 2015 Jul;152(2):399-405. doi: 10.1007/s10549-015-3466-4. Epub 2015 Jul 1.

PMID:
26126970
30.

Triple-negative breast cancer: molecular subtypes and new targets for therapy.

Lehmann BD, Pietenpol JA, Tan AR.

Am Soc Clin Oncol Educ Book. 2015:e31-9. doi: 10.14694/EdBook_AM.2015.35.e31.

31.

Fabrication of tissue engineered osteochondral grafts for restoring the articular surface of diarthrodial joints.

Roach BL, Hung CT, Cook JL, Ateshian GA, Tan AR.

Methods. 2015 Aug;84:103-8. doi: 10.1016/j.ymeth.2015.03.008. Epub 2015 Mar 17.

32.

Human chondrocyte migration behaviour to guide the development of engineered cartilage.

O'Connell GD, Tan AR, Cui V, Bulinski JC, Cook JL, Attur M, Abramson SB, Ateshian GA, Hung CT.

J Tissue Eng Regen Med. 2017 Mar;11(3):877-886. doi: 10.1002/term.1988. Epub 2015 Jan 28.

33.

Cutaneous keratoacanthomas/squamous cell carcinomas associated with neutralization of transforming growth factor β by the monoclonal antibody fresolimumab (GC1008).

Lacouture ME, Morris JC, Lawrence DP, Tan AR, Olencki TE, Shapiro GI, Dezube BJ, Berzofsky JA, Hsu FJ, Guitart J.

Cancer Immunol Immunother. 2015 Apr;64(4):437-46. doi: 10.1007/s00262-015-1653-0. Epub 2015 Jan 13.

34.

Weekly paclitaxel and concurrent pazopanib following doxorubicin and cyclophosphamide as neoadjuvant therapy for HER-negative locally advanced breast cancer: NSABP Foundation FB-6, a phase II study.

Tan AR, Johannes H, Rastogi P, Jacobs SA, Robidoux A, Flynn PJ, Thirlwell MP, Fehrenbacher L, Stella PJ, Goel R, Julian TB, Provencher L, Bury MJ, Bhatt K, Geyer CE Jr, Swain SM, Mamounas EP, Wolmark N.

Breast Cancer Res Treat. 2015 Jan;149(1):163-9. doi: 10.1007/s10549-014-3221-2. Epub 2014 Dec 27.

PMID:
25542269
35.

Passage-dependent relationship between mesenchymal stem cell mobilization and chondrogenic potential.

Tan AR, Alegre-Aguarón E, O'Connell GD, VandenBerg CD, Aaron RK, Vunjak-Novakovic G, Chloe Bulinski J, Ateshian GA, Hung CT.

Osteoarthritis Cartilage. 2015 Feb;23(2):319-27. doi: 10.1016/j.joca.2014.10.001. Epub 2014 Oct 17.

36.

Spectrum and burden of movement disorder conditions in a tertiary movement disorders centre--a 10-year trend.

Eu KM, Tan LC, Tan AR, Seah IS, Lau PN, Li W, Au WL, Tay KY.

Ann Acad Med Singapore. 2014 Apr;43(4):203-8.

37.

Phase I study of weekly paclitaxel in combination with pazopanib and lapatinib in advanced solid malignancies.

Tan AR, Dowlati A, Stein MN, Jones SF, Infante JR, Bendell J, Kane MP, Levinson KT, Suttle AB, Burris HA 3rd.

Br J Cancer. 2014 May 27;110(11):2647-54. doi: 10.1038/bjc.2014.233. Epub 2014 May 6.

38.

Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFβ) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma.

Morris JC, Tan AR, Olencki TE, Shapiro GI, Dezube BJ, Reiss M, Hsu FJ, Berzofsky JA, Lawrence DP.

PLoS One. 2014 Mar 11;9(3):e90353. doi: 10.1371/journal.pone.0090353. eCollection 2014.

39.

Safety and efficacy of neratinib in combination with weekly paclitaxel and trastuzumab in women with metastatic HER2‑positive breast cancer: an NSABP Foundation Research Program phase I study.

Jankowitz RC, Abraham J, Tan AR, Limentani SA, Tierno MB, Adamson LM, Buyse M, Wolmark N, Jacobs SA.

Cancer Chemother Pharmacol. 2013 Dec;72(6):1205-12.

PMID:
24077916
40.

Tripartite Motif-containing 33 (TRIM33) protein functions in the poly(ADP-ribose) polymerase (PARP)-dependent DNA damage response through interaction with Amplified in Liver Cancer 1 (ALC1) protein.

Kulkarni A, Oza J, Yao M, Sohail H, Ginjala V, Tomas-Loba A, Horejsi Z, Tan AR, Boulton SJ, Ganesan S.

J Biol Chem. 2013 Nov 8;288(45):32357-69. doi: 10.1074/jbc.M113.459164. Epub 2013 Aug 6.

41.

Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors.

Tan AR, Gibbon DG, Stein MN, Lindquist D, Edenfield JW, Martin JC, Gregory C, Suttle AB, Tada H, Botbyl J, Stephenson JJ.

Cancer Chemother Pharmacol. 2013 Jun;71(6):1635-43. doi: 10.1007/s00280-013-2164-3. Epub 2013 May 1.

PMID:
23636448
42.

A randomized, double-blind, placebo-controlled study to evaluate the effect of repeated oral doses of pazopanib on cardiac conduction in patients with solid tumors.

Heath EI, Infante J, Lewis LD, Luu T, Stephenson J, Tan AR, Kasubhai S, LoRusso P, Ma B, Suttle AB, Kleha JF, Ball HA, Dar MM.

Cancer Chemother Pharmacol. 2013 Mar;71(3):565-73. doi: 10.1007/s00280-012-2030-8. Epub 2013 Jan 24.

43.

Phase I study of pazopanib in combination with paclitaxel and carboplatin given every 21 days in patients with advanced solid tumors.

Burris HA 3rd, Dowlati A, Moss RA, Infante JR, Jones SF, Spigel DR, Levinson KT, Lindquist D, Gainer SD, Dar MM, Suttle AB, Ball HA, Tan AR.

Mol Cancer Ther. 2012 Aug;11(8):1820-8. doi: 10.1158/1535-7163.MCT-11-0997. Epub 2012 Jun 7.

44.

A phase 1 trial of E7974 administered on day 1 of a 21-day cycle in patients with advanced solid tumors.

Rocha-Lima CM, Bayraktar S, Macintyre J, Raez L, Flores AM, Ferrell A, Rubin EH, Poplin EA, Tan AR, Lucarelli A, Zojwalla N.

Cancer. 2012 Sep 1;118(17):4262-70. doi: 10.1002/cncr.27428. Epub 2012 Jan 31.

45.

Pazopanib for the treatment of breast cancer.

Amiri-Kordestani L, Tan AR, Swain SM.

Expert Opin Investig Drugs. 2012 Feb;21(2):217-25. doi: 10.1517/13543784.2012.652304. Epub 2012 Jan 10. Review.

PMID:
22233389
46.

Protein monoubiquitination and polyubiquitination generate structural diversity to control distinct biological processes.

Sadowski M, Suryadinata R, Tan AR, Roesley SN, Sarcevic B.

IUBMB Life. 2012 Feb;64(2):136-42. doi: 10.1002/iub.589. Epub 2011 Nov 30. Review.

47.

Rationally designed treatment for solid tumors with MAPK pathway activation: a phase I study of paclitaxel and bortezomib using an adaptive dose-finding approach.

Mehnert JM, Tan AR, Moss R, Poplin E, Stein MN, Sovak M, Levinson K, Lin H, Kane M, Gounder M, Lin Y, Shih WJ, White E, Rubin EH, Karantza V.

Mol Cancer Ther. 2011 Aug;10(8):1509-19. doi: 10.1158/1535-7163.MCT-10-0944. Epub 2011 Jun 16.

48.

A phase I trial of MK-0731, a kinesin spindle protein (KSP) inhibitor, in patients with solid tumors.

Holen K, DiPaola R, Liu G, Tan AR, Wilding G, Hsu K, Agrawal N, Chen C, Xue L, Rosenberg E, Stein M.

Invest New Drugs. 2012 Jun;30(3):1088-95. doi: 10.1007/s10637-011-9653-1. Epub 2011 Mar 22.

49.

Bioactive glass 13-93 as a subchondral substrate for tissue-engineered osteochondral constructs: a pilot study.

Jayabalan P, Tan AR, Rahaman MN, Bal BS, Hung CT, Cook JL.

Clin Orthop Relat Res. 2011 Oct;469(10):2754-63. doi: 10.1007/s11999-011-1818-x.

50.

Coculture of engineered cartilage with primary chondrocytes induces expedited growth.

Tan AR, Dong EY, Andry JP, Bulinski JC, Ateshian GA, Hung CT.

Clin Orthop Relat Res. 2011 Oct;469(10):2735-43. doi: 10.1007/s11999-011-1772-7.

Supplemental Content

Support Center